In order to boost its oncology portfolio, Ipsen has entered into an agreement to acquire Merrimack’s pancreatic cancer drug Onivyde® (irinotecan liposome injection) and its Doxil generic, along with its commercial and marketing infrastructure for up to US$1B. Besides US rights, Ipsen also gains Merrimack’s licensing agreements for Onivyde in different geographies. The deal is part of a corporate-wide re-organisation drive at Merrimack to become a clinical stage oncology company with focus on three candidates – MM-121, MM-141 and MM-310.